Life-Threatening Diseases Compassion through Combination Therapy Act of 2012 (H.R. 6502)

Legislation co-sponsored by Representatives Brian Bilbray (R-CA), Carolyn Maloney (D-NY) and Rosa DeLauro (D-CT), and supported by the Melanoma Research Foundation, seeks to encourage the development of so-called “significant drug combinations” by offering the carrot of an extension of marketing exclusivity.

More Information:

FDA Law Blog:  New Legislation Would Provide Exclusivity Add-on for Significant Drug Combinations

Melanoma Research Foundation Press Release:  Members of Congress Introduce Legislation That Would Support Development of Life-Saving Combination Therapies

Track the bill @ RDLA’s Legislative Action Center:  HR 6502